News
Q1 2026 Earnings Call Transcript June 6, 2025 Operator: Good afternoon, ladies and gentlemen. Thank you for joining ...
AnaptysBio, Inc.'s rosnilimab shows promise in RA & ulcerative colitis, targeting $20B+ markets. Phase 2b results highlight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback